Johns Hopkins ABX Guide
Zanamivir
INDICATIONS
FDA
FDA
- Uncomplicated acute illness due to influenza A and B infection (patients ≥ 7 years of age with ≤ 48 hours of symptoms).
- Clinical benefit is best established when treatment is initiated within 48 hours of symptom onset in uncomplicated influenza.
- It is FDA-approved for treatment in patients aged 7 years and older, but use is limited by inhaled administration and is not recommended in patients with asthma, COPD, or other underlying airway disease.
- Influenza prophylaxis in those 5 years of age or older.
- Not proven effective for prophylaxis in nursing home residents.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 6, 2026
Citation
Tsai, Y. V, and Paul G Auwaerter. "Zanamivir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2026. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540596/all/Zanamivir.
Tsai YV, Auwaerter PG. Zanamivir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540596/all/Zanamivir. Accessed September 20, 2026.
Tsai, Y. V., & Auwaerter, P. G. (2026). Zanamivir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540596/all/Zanamivir
Tsai YV, Auwaerter PG. Zanamivir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. [cited 2026 September 20]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540596/all/Zanamivir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Zanamivir
ID - 540596
A1 - Tsai,Y.,Pharm.D.
AU - Auwaerter,Paul,M.D.
Y1 - 2026/09/06/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540596/all/Zanamivir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
